Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related cardiovascular diseases (CVD). This comprehensive review delineates the intricate roles and wide-ranging...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-01-01
|
| Series: | Signal Transduction and Targeted Therapy |
| Online Access: | https://doi.org/10.1038/s41392-023-01690-3 |
| _version_ | 1827381933037846528 |
|---|---|
| author | Xuhui Bao Yongjun Liang Hanman Chang Tianji Cai Baijie Feng Konstantin Gordon Yuekun Zhu Hailian Shi Yundong He Liyi Xie |
| author_facet | Xuhui Bao Yongjun Liang Hanman Chang Tianji Cai Baijie Feng Konstantin Gordon Yuekun Zhu Hailian Shi Yundong He Liyi Xie |
| author_sort | Xuhui Bao |
| collection | DOAJ |
| description | Abstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related cardiovascular diseases (CVD). This comprehensive review delineates the intricate roles and wide-ranging implications of PCSK9, extending beyond CVD to emphasize its significance in diverse physiological and pathological states, including liver diseases, infectious diseases, autoimmune disorders, and notably, cancer. Our exploration offers insights into the interaction between PCSK9 and low-density lipoprotein receptors (LDLRs), elucidating its substantial impact on cholesterol homeostasis and cardiovascular health. It also details the evolution of PCSK9-targeted therapies, translating foundational bench discoveries into bedside applications for optimized patient care. The advent and clinical approval of innovative PCSK9 inhibitory therapies (PCSK9-iTs), including three monoclonal antibodies (Evolocumab, Alirocumab, and Tafolecimab) and one small interfering RNA (siRNA, Inclisiran), have marked a significant breakthrough in cardiovascular medicine. These therapies have demonstrated unparalleled efficacy in mitigating hypercholesterolemia, reducing cardiovascular risks, and have showcased profound value in clinical applications, offering novel therapeutic avenues and a promising future in personalized medicine for cardiovascular disorders. Furthermore, emerging research, inclusive of our findings, unveils PCSK9’s potential role as a pivotal indicator for cancer prognosis and its prospective application as a transformative target for cancer treatment. This review also highlights PCSK9’s aberrant expression in various cancer forms, its association with cancer prognosis, and its crucial roles in carcinogenesis and cancer immunity. In conclusion, this synthesized review integrates existing knowledge and novel insights on PCSK9, providing a holistic perspective on its transformative impact in reshaping therapeutic paradigms across various disorders. It emphasizes the clinical value and effect of PCSK9-iT, underscoring its potential in advancing the landscape of biomedical research and its capabilities in heralding new eras in personalized medicine. |
| first_indexed | 2024-03-08T14:12:08Z |
| format | Article |
| id | doaj.art-6181cf680aaa49b0bebe72d6360e60bc |
| institution | Directory Open Access Journal |
| issn | 2059-3635 |
| language | English |
| last_indexed | 2024-03-08T14:12:08Z |
| publishDate | 2024-01-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Signal Transduction and Targeted Therapy |
| spelling | doaj.art-6181cf680aaa49b0bebe72d6360e60bc2024-01-14T12:38:07ZengNature Publishing GroupSignal Transduction and Targeted Therapy2059-36352024-01-019114910.1038/s41392-023-01690-3Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedsideXuhui Bao0Yongjun Liang1Hanman Chang2Tianji Cai3Baijie Feng4Konstantin Gordon5Yuekun Zhu6Hailian Shi7Yundong He8Liyi Xie9Institute of Therapeutic Cancer Vaccines, Fudan University Pudong Medical CenterCenter for Medical Research and Innovation, Fudan University Pudong Medical CenterInstitute for Food Safety and Health, Illinois Institute of TechnologyDepartment of Sociology, University of MacauDepartment of Oncology, Fudan University Pudong Medical CenterMedical Institute, Peoples’ Friendship University of RussiaDepartment of Colorectal Surgery, The First Affiliated Hospital of Harbin Medical UniversityShanghai Key Laboratory of Compound Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Zhangjiang Hi-tech ParkShanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal UniversityDepartment of Radiation Oncology, Fudan University Shanghai Cancer CenterAbstract Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related cardiovascular diseases (CVD). This comprehensive review delineates the intricate roles and wide-ranging implications of PCSK9, extending beyond CVD to emphasize its significance in diverse physiological and pathological states, including liver diseases, infectious diseases, autoimmune disorders, and notably, cancer. Our exploration offers insights into the interaction between PCSK9 and low-density lipoprotein receptors (LDLRs), elucidating its substantial impact on cholesterol homeostasis and cardiovascular health. It also details the evolution of PCSK9-targeted therapies, translating foundational bench discoveries into bedside applications for optimized patient care. The advent and clinical approval of innovative PCSK9 inhibitory therapies (PCSK9-iTs), including three monoclonal antibodies (Evolocumab, Alirocumab, and Tafolecimab) and one small interfering RNA (siRNA, Inclisiran), have marked a significant breakthrough in cardiovascular medicine. These therapies have demonstrated unparalleled efficacy in mitigating hypercholesterolemia, reducing cardiovascular risks, and have showcased profound value in clinical applications, offering novel therapeutic avenues and a promising future in personalized medicine for cardiovascular disorders. Furthermore, emerging research, inclusive of our findings, unveils PCSK9’s potential role as a pivotal indicator for cancer prognosis and its prospective application as a transformative target for cancer treatment. This review also highlights PCSK9’s aberrant expression in various cancer forms, its association with cancer prognosis, and its crucial roles in carcinogenesis and cancer immunity. In conclusion, this synthesized review integrates existing knowledge and novel insights on PCSK9, providing a holistic perspective on its transformative impact in reshaping therapeutic paradigms across various disorders. It emphasizes the clinical value and effect of PCSK9-iT, underscoring its potential in advancing the landscape of biomedical research and its capabilities in heralding new eras in personalized medicine.https://doi.org/10.1038/s41392-023-01690-3 |
| spellingShingle | Xuhui Bao Yongjun Liang Hanman Chang Tianji Cai Baijie Feng Konstantin Gordon Yuekun Zhu Hailian Shi Yundong He Liyi Xie Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside Signal Transduction and Targeted Therapy |
| title | Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside |
| title_full | Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside |
| title_fullStr | Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside |
| title_full_unstemmed | Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside |
| title_short | Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside |
| title_sort | targeting proprotein convertase subtilisin kexin type 9 pcsk9 from bench to bedside |
| url | https://doi.org/10.1038/s41392-023-01690-3 |
| work_keys_str_mv | AT xuhuibao targetingproproteinconvertasesubtilisinkexintype9pcsk9frombenchtobedside AT yongjunliang targetingproproteinconvertasesubtilisinkexintype9pcsk9frombenchtobedside AT hanmanchang targetingproproteinconvertasesubtilisinkexintype9pcsk9frombenchtobedside AT tianjicai targetingproproteinconvertasesubtilisinkexintype9pcsk9frombenchtobedside AT baijiefeng targetingproproteinconvertasesubtilisinkexintype9pcsk9frombenchtobedside AT konstantingordon targetingproproteinconvertasesubtilisinkexintype9pcsk9frombenchtobedside AT yuekunzhu targetingproproteinconvertasesubtilisinkexintype9pcsk9frombenchtobedside AT hailianshi targetingproproteinconvertasesubtilisinkexintype9pcsk9frombenchtobedside AT yundonghe targetingproproteinconvertasesubtilisinkexintype9pcsk9frombenchtobedside AT liyixie targetingproproteinconvertasesubtilisinkexintype9pcsk9frombenchtobedside |